Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Avery A Rizio, Michelle K White, Anita D’Souza, Kristen Hsu, Paula Schmitt, Tiffany P Quock, James Signorovitch, Isabelle Lousada & Vaishali Sanchorawala. (2023) Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group. Patient Related Outcome Measures 14, pages 153-169.
Read now
Read now
Victor H. Jimenez-Zepeda, Donna Reece, Rodrigo Rigo, Priyanka Gogna, Shiying Kong, Xun Yang Hu, Parv Chapani, Winson Y. Cheung, Darren R. Brenner, Richard Plante, Kun Shi, Asad Husain, Eric Ammann, Dipti Tankala & Devon J. Boyne. (2023) Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data. Leukemia & Lymphoma 64:1, pages 256-258.
Read now
Read now
Parameswaran Hari, Huamao Mark Lin, Carl V. Asche, Jinma Ren, Candice Yong, Katarina Luptakova, Douglas V. Faller & Vaishali Sanchorawala. (2018) Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis . Amyloid 25:1, pages 1-7.
Read now
Read now
Articles from other publishers (17)
Alice Sabinot, Gianni Ghetti, Lorenzo Pradelli, Stefania Bellucci, Antonella Lausi & Giovanni Palladini. (2023) State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Reviews 59, pages 101040.
Crossref
Crossref
Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan O. Schönland, Heather J. Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Dasha Cherepanov, Vanessa C. Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller & Efstathios Kastritis. (2023)
Quality of life and symptoms among patients with relapsed/refractory
AL
amyloidosis treated with
ixazomib‐dexamethasone
versus physician's choice
. American Journal of Hematology 98:5, pages 720-729.
Crossref
Crossref
Tiffany P Quock, Anita D'Souza, Michael S Broder, Katalin Bognar, Eunice Chang & Marian H Tarbox. (2023) In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database. Journal of Comparative Effectiveness Research 12:2.
Crossref
Crossref
Nishant Kumar, Nicole J. Zhang, Dasha Cherepanov, Dorothy Romanus, Michael Hughes & Douglas V. Faller. (2022) Global epidemiology of amyloid light-chain amyloidosis. Orphanet Journal of Rare Diseases 17:1.
Crossref
Crossref
Ashutosh D. Wechalekar, Marianna Fontana, C. Cristina Quarta & Michaela Liedtke. (2022) AL Amyloidosis for Cardiologists. JACC: CardioOncology 4:4, pages 427-441.
Crossref
Crossref
Lindsay N. Moy, Mahum Mirza, Blake Moskal, Nahren Asado, Bhaven Shah & Jacob Bitran. (2022) Pulmonary AL amyloidosis: A review and update on treatment options. Annals of Medicine and Surgery 80, pages 104060.
Crossref
Crossref
Charlene Lee, Annette Lam, Teresa Kangappaden, Pyper Olver, Sarah Kane, Diana Tran & Eric Ammann. (2022) Systematic literature review of evidence in amyloid light-chain amyloidosis. Journal of Comparative Effectiveness Research 11:6, pages 451-472.
Crossref
Crossref
Hamza Hassan & Vaishali Sanchorawala. (2022) Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs. Hemato 3:1, pages 38-46.
Crossref
Crossref
Roxana Cristina Rimbas, Anca Balinisteanu, Alexandra Maria Chitroceanu & Dragos Vinereanu. (2021) Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options. Romanian Journal of Cardiology 31:2, pages 283-302.
Crossref
Crossref
Sameer Arora, Nikita S. Patil, Paula D. Strassle, Arman Qamar, Muthiah Vaduganathan, Amber Fatima, Kalyan Mogili, Deepak Garipalli, Justin L. Grodin, John P. Vavalle, Gregg C. Fonarow, Deepak L. Bhatt & Ambarish Pandey. (2020) Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure. JACC: CardioOncology 2:5, pages 710-718.
Crossref
Crossref
Morie A. Gertz & Angela Dispenzieri. (2020) Systemic Amyloidosis Recognition, Prognosis, and Therapy. JAMA 324:1, pages 79.
Crossref
Crossref
Bennett Di Giovanni, Dakota Gustafson, Mitchell B. Adamson & Diego H. Delgado. (2020) Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic. Canadian Journal of Cardiology 36:3, pages 373-383.
Crossref
Crossref
Baojian Liu, Ming Bai, Yan Wang, Di Wang, Jin Zhao, Lu Li, Ruijuan Dong & Shiren Sun. (2019) The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis. European Journal of Internal Medicine 69, pages 32-41.
Crossref
Crossref
Kristen L. McCausland, Avery A. Rizio, Michelle K. White, Martha S. Bayliss & Tiffany P. Quock. (2019) Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis. PharmacoEconomics - Open 3:3, pages 367-375.
Crossref
Crossref
Baojian Liu, Yan Wang, Ming Bai, Di Wang, Jin Zhao, Ming Zhang & Shiren Sun. (2019) Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. Clinical Therapeutics 41:6, pages 1186-1198.
Crossref
Crossref
Tiffany P Quock, Tingjian Yan, Eunice Chang, Spencer Guthrie & Michael S Broder. (2018) Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data. Journal of Comparative Effectiveness Research 7:6, pages 549-559.
Crossref
Crossref
Tiffany P. QuockTingjian Yan, Eunice Chang, Spencer Guthrie & Michael S. Broder. (2018) Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Advances 2:10, pages 1046-1053.
Crossref
Crossref